Global CRISPR and CRISPR-Associated (Cas) Genes Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Summary
This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.
Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of 'spacer DNA' from previous exposures to a bacteriophage virus or plasmid.
The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.
Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.
By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.
According to APO Research, The global CRISPR and CRISPR-Associated (Cas) Genes market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of CRISPR and CRISPR-Associated (Cas) Genes include Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics, Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich and Precision Biosciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for CRISPR and CRISPR-Associated (Cas) Genes, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of CRISPR and CRISPR-Associated (Cas) Genes, also provides the value of main regions and countries. Of the upcoming market potential for CRISPR and CRISPR-Associated (Cas) Genes, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the CRISPR and CRISPR-Associated (Cas) Genes revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global CRISPR and CRISPR-Associated (Cas) Genes market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global CRISPR and CRISPR-Associated (Cas) Genes company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
CRISPR and CRISPR-Associated (Cas) Genes segment by Company
1. To analyze and research the global CRISPR and CRISPR-Associated (Cas) Genes status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the CRISPR and CRISPR-Associated (Cas) Genes key companies, revenue, market share, and recent developments.
3. To split the CRISPR and CRISPR-Associated (Cas) Genes breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions CRISPR and CRISPR-Associated (Cas) Genes market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify CRISPR and CRISPR-Associated (Cas) Genes significant trends, drivers, influence factors in global and regions.
6. To analyze CRISPR and CRISPR-Associated (Cas) Genes competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CRISPR and CRISPR-Associated (Cas) Genes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CRISPR and CRISPR-Associated (Cas) Genes and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CRISPR and CRISPR-Associated (Cas) Genes.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CRISPR and CRISPR-Associated (Cas) Genes industry.
Chapter 3: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of CRISPR and CRISPR-Associated (Cas) Genes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of CRISPR and CRISPR-Associated (Cas) Genes in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.
Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of 'spacer DNA' from previous exposures to a bacteriophage virus or plasmid.
The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.
Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.
By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.
According to APO Research, The global CRISPR and CRISPR-Associated (Cas) Genes market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for CRISPR and CRISPR-Associated (Cas) Genes is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of CRISPR and CRISPR-Associated (Cas) Genes include Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics, Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich and Precision Biosciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for CRISPR and CRISPR-Associated (Cas) Genes, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of CRISPR and CRISPR-Associated (Cas) Genes, also provides the value of main regions and countries. Of the upcoming market potential for CRISPR and CRISPR-Associated (Cas) Genes, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the CRISPR and CRISPR-Associated (Cas) Genes revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global CRISPR and CRISPR-Associated (Cas) Genes market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global CRISPR and CRISPR-Associated (Cas) Genes company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
CRISPR and CRISPR-Associated (Cas) Genes segment by Company
- Thermo Fisher Scientific
- Editas Medicine
- Caribou Biosciences
- CRISPR therapeutics
- Intellia therapeutics, Inc.
- Cellectis
- Horizon Discovery Plc
- Sigma Aldrich
- Precision Biosciences
- Genscript
- Sangamo Biosciences Inc.
- Lonza Group Limited
- Integrated DNA Technologies
- New England Biolabs
- Origene Technologies
- Genome Editing
- Genetic engineering
- gRNA Database/Gene Librar
- CRISPR Plasmid
- Human Stem Cells
- Genetically Modified Organisms/Crops
- Cell Line Engineering
- Biotechnology Companies
- Pharmaceutical Companies
- Academic Institutes
- Research and Development Institutes
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global CRISPR and CRISPR-Associated (Cas) Genes status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the CRISPR and CRISPR-Associated (Cas) Genes key companies, revenue, market share, and recent developments.
3. To split the CRISPR and CRISPR-Associated (Cas) Genes breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions CRISPR and CRISPR-Associated (Cas) Genes market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify CRISPR and CRISPR-Associated (Cas) Genes significant trends, drivers, influence factors in global and regions.
6. To analyze CRISPR and CRISPR-Associated (Cas) Genes competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CRISPR and CRISPR-Associated (Cas) Genes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CRISPR and CRISPR-Associated (Cas) Genes and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CRISPR and CRISPR-Associated (Cas) Genes.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CRISPR and CRISPR-Associated (Cas) Genes industry.
Chapter 3: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of CRISPR and CRISPR-Associated (Cas) Genes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of CRISPR and CRISPR-Associated (Cas) Genes in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size, 2019 VS 2023 VS 2030
1.3 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET DYNAMICS
2.1 CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
2.2 CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
2.3 CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
2.4 CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints
3 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY COMPANY
3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Company Revenue Ranking in 2023
3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Company (2019-2024)
3.3 Global CRISPR and CRISPR-Associated (Cas) Genes Company Ranking, 2022 VS 2023 VS 2024
3.4 Global CRISPR and CRISPR-Associated (Cas) Genes Company Manufacturing Base & Headquarters
3.5 Global CRISPR and CRISPR-Associated (Cas) Genes Company, Product Type & Application
3.6 Global CRISPR and CRISPR-Associated (Cas) Genes Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 CRISPR and CRISPR-Associated (Cas) Genes Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY TYPE
4.1 CRISPR and CRISPR-Associated (Cas) Genes Type Introduction
4.1.1 Genome Editing
4.1.2 Genetic engineering
4.1.3 gRNA Database/Gene Librar
4.1.4 CRISPR Plasmid
4.1.5 Human Stem Cells
4.1.6 Genetically Modified Organisms/Crops
4.1.7 Cell Line Engineering
4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type
4.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019-2030)
4.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2019-2030)
5 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY APPLICATION
5.1 CRISPR and CRISPR-Associated (Cas) Genes Application Introduction
5.1.1 Biotechnology Companies
5.1.2 Pharmaceutical Companies
5.1.3 Academic Institutes
5.1.4 Research and Development Institutes
5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application
5.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019-2030)
5.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2019-2030)
6 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY REGION
6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2019-2030)
6.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region: 2019-2024
6.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)
6.3.2 North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)
6.4.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)
6.5.2 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)
6.6.2 Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)
6.7.2 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030
7 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY COUNTRY
7.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2019-2030)
7.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2019-2024)
7.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.3.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.4.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.5.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.6.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.7.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.7.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.8.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.8.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.9.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.9.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.10.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.10.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.11.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.11.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.12.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.12.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.13.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.13.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.14.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.14.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.15.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.15.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.16.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.16.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.17.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.17.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.18.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.18.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.19.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.19.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.20.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.20.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.21.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.21.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Thermo Fisher Scientific
8.1.1 Thermo Fisher Scientific Comapny Information
8.1.2 Thermo Fisher Scientific Business Overview
8.1.3 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.1.4 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.1.5 Thermo Fisher Scientific Recent Developments
8.2 Editas Medicine
8.2.1 Editas Medicine Comapny Information
8.2.2 Editas Medicine Business Overview
8.2.3 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.2.4 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.2.5 Editas Medicine Recent Developments
8.3 Caribou Biosciences
8.3.1 Caribou Biosciences Comapny Information
8.3.2 Caribou Biosciences Business Overview
8.3.3 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.3.4 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.3.5 Caribou Biosciences Recent Developments
8.4 CRISPR therapeutics
8.4.1 CRISPR therapeutics Comapny Information
8.4.2 CRISPR therapeutics Business Overview
8.4.3 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.4.4 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.4.5 CRISPR therapeutics Recent Developments
8.5 Intellia therapeutics, Inc.
8.5.1 Intellia therapeutics, Inc. Comapny Information
8.5.2 Intellia therapeutics, Inc. Business Overview
8.5.3 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.5.4 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.5.5 Intellia therapeutics, Inc. Recent Developments
8.6 Cellectis
8.6.1 Cellectis Comapny Information
8.6.2 Cellectis Business Overview
8.6.3 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.6.4 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.6.5 Cellectis Recent Developments
8.7 Horizon Discovery Plc
8.7.1 Horizon Discovery Plc Comapny Information
8.7.2 Horizon Discovery Plc Business Overview
8.7.3 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.7.4 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.7.5 Horizon Discovery Plc Recent Developments
8.8 Sigma Aldrich
8.8.1 Sigma Aldrich Comapny Information
8.8.2 Sigma Aldrich Business Overview
8.8.3 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.8.4 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.8.5 Sigma Aldrich Recent Developments
8.9 Precision Biosciences
8.9.1 Precision Biosciences Comapny Information
8.9.2 Precision Biosciences Business Overview
8.9.3 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.9.4 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.9.5 Precision Biosciences Recent Developments
8.10 Genscript
8.10.1 Genscript Comapny Information
8.10.2 Genscript Business Overview
8.10.3 Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.10.4 Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.10.5 Genscript Recent Developments
8.11 Sangamo Biosciences Inc.
8.11.1 Sangamo Biosciences Inc. Comapny Information
8.11.2 Sangamo Biosciences Inc. Business Overview
8.11.3 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.11.4 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.11.5 Sangamo Biosciences Inc. Recent Developments
8.12 Lonza Group Limited
8.12.1 Lonza Group Limited Comapny Information
8.12.2 Lonza Group Limited Business Overview
8.12.3 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.12.4 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.12.5 Lonza Group Limited Recent Developments
8.13 Integrated DNA Technologies
8.13.1 Integrated DNA Technologies Comapny Information
8.13.2 Integrated DNA Technologies Business Overview
8.13.3 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.13.4 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.13.5 Integrated DNA Technologies Recent Developments
8.14 New England Biolabs
8.14.1 New England Biolabs Comapny Information
8.14.2 New England Biolabs Business Overview
8.14.3 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.14.4 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.14.5 New England Biolabs Recent Developments
8.15 Origene Technologies
8.15.1 Origene Technologies Comapny Information
8.15.2 Origene Technologies Business Overview
8.15.3 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.15.4 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.15.5 Origene Technologies Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
1.1 Product Definition
1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size, 2019 VS 2023 VS 2030
1.3 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET DYNAMICS
2.1 CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
2.2 CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
2.3 CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
2.4 CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints
3 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY COMPANY
3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Company Revenue Ranking in 2023
3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Company (2019-2024)
3.3 Global CRISPR and CRISPR-Associated (Cas) Genes Company Ranking, 2022 VS 2023 VS 2024
3.4 Global CRISPR and CRISPR-Associated (Cas) Genes Company Manufacturing Base & Headquarters
3.5 Global CRISPR and CRISPR-Associated (Cas) Genes Company, Product Type & Application
3.6 Global CRISPR and CRISPR-Associated (Cas) Genes Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 CRISPR and CRISPR-Associated (Cas) Genes Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY TYPE
4.1 CRISPR and CRISPR-Associated (Cas) Genes Type Introduction
4.1.1 Genome Editing
4.1.2 Genetic engineering
4.1.3 gRNA Database/Gene Librar
4.1.4 CRISPR Plasmid
4.1.5 Human Stem Cells
4.1.6 Genetically Modified Organisms/Crops
4.1.7 Cell Line Engineering
4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type
4.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019-2030)
4.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2019-2030)
5 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY APPLICATION
5.1 CRISPR and CRISPR-Associated (Cas) Genes Application Introduction
5.1.1 Biotechnology Companies
5.1.2 Pharmaceutical Companies
5.1.3 Academic Institutes
5.1.4 Research and Development Institutes
5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application
5.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019-2030)
5.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2019-2030)
6 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY REGION
6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2019-2030)
6.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region: 2019-2024
6.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)
6.3.2 North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)
6.4.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)
6.5.2 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)
6.6.2 Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030)
6.7.2 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2023 VS 2030
7 CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET BY COUNTRY
7.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2019-2030)
7.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2019-2024)
7.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.3.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.4.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.5.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.6.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.7.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.7.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.8.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.8.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.9.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.9.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.10.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.10.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.11.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.11.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.12.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.12.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.13.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.13.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.14.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.14.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.15.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.15.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.16.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.16.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.17.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.17.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.18.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.18.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.19.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.19.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.20.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.20.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030)
7.21.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030
7.21.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Thermo Fisher Scientific
8.1.1 Thermo Fisher Scientific Comapny Information
8.1.2 Thermo Fisher Scientific Business Overview
8.1.3 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.1.4 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.1.5 Thermo Fisher Scientific Recent Developments
8.2 Editas Medicine
8.2.1 Editas Medicine Comapny Information
8.2.2 Editas Medicine Business Overview
8.2.3 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.2.4 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.2.5 Editas Medicine Recent Developments
8.3 Caribou Biosciences
8.3.1 Caribou Biosciences Comapny Information
8.3.2 Caribou Biosciences Business Overview
8.3.3 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.3.4 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.3.5 Caribou Biosciences Recent Developments
8.4 CRISPR therapeutics
8.4.1 CRISPR therapeutics Comapny Information
8.4.2 CRISPR therapeutics Business Overview
8.4.3 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.4.4 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.4.5 CRISPR therapeutics Recent Developments
8.5 Intellia therapeutics, Inc.
8.5.1 Intellia therapeutics, Inc. Comapny Information
8.5.2 Intellia therapeutics, Inc. Business Overview
8.5.3 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.5.4 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.5.5 Intellia therapeutics, Inc. Recent Developments
8.6 Cellectis
8.6.1 Cellectis Comapny Information
8.6.2 Cellectis Business Overview
8.6.3 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.6.4 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.6.5 Cellectis Recent Developments
8.7 Horizon Discovery Plc
8.7.1 Horizon Discovery Plc Comapny Information
8.7.2 Horizon Discovery Plc Business Overview
8.7.3 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.7.4 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.7.5 Horizon Discovery Plc Recent Developments
8.8 Sigma Aldrich
8.8.1 Sigma Aldrich Comapny Information
8.8.2 Sigma Aldrich Business Overview
8.8.3 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.8.4 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.8.5 Sigma Aldrich Recent Developments
8.9 Precision Biosciences
8.9.1 Precision Biosciences Comapny Information
8.9.2 Precision Biosciences Business Overview
8.9.3 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.9.4 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.9.5 Precision Biosciences Recent Developments
8.10 Genscript
8.10.1 Genscript Comapny Information
8.10.2 Genscript Business Overview
8.10.3 Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.10.4 Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.10.5 Genscript Recent Developments
8.11 Sangamo Biosciences Inc.
8.11.1 Sangamo Biosciences Inc. Comapny Information
8.11.2 Sangamo Biosciences Inc. Business Overview
8.11.3 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.11.4 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.11.5 Sangamo Biosciences Inc. Recent Developments
8.12 Lonza Group Limited
8.12.1 Lonza Group Limited Comapny Information
8.12.2 Lonza Group Limited Business Overview
8.12.3 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.12.4 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.12.5 Lonza Group Limited Recent Developments
8.13 Integrated DNA Technologies
8.13.1 Integrated DNA Technologies Comapny Information
8.13.2 Integrated DNA Technologies Business Overview
8.13.3 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.13.4 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.13.5 Integrated DNA Technologies Recent Developments
8.14 New England Biolabs
8.14.1 New England Biolabs Comapny Information
8.14.2 New England Biolabs Business Overview
8.14.3 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.14.4 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.14.5 New England Biolabs Recent Developments
8.15 Origene Technologies
8.15.1 Origene Technologies Comapny Information
8.15.2 Origene Technologies Business Overview
8.15.3 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2019-2024)
8.15.4 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
8.15.5 Origene Technologies Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
LIST OF TABLES
Table 1. CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
Table 2. CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
Table 3. CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
Table 4. CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints
Table 5. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Company (2019-2024)
Table 7. Global CRISPR and CRISPR-Associated (Cas) Genes Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global CRISPR and CRISPR-Associated (Cas) Genes Key Company Manufacturing Base & Headquarters
Table 9. Global CRISPR and CRISPR-Associated (Cas) Genes Company, Product Type & Application
Table 10. Global CRISPR and CRISPR-Associated (Cas) Genes Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global CRISPR and CRISPR-Associated (Cas) Genes by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Genome Editing
Table 15. Major Companies of Genetic engineering
Table 16. Major Companies of gRNA Database/Gene Librar
Table 17. Major Companies of CRISPR Plasmid
Table 18. Major Companies of Human Stem Cells
Table 19. Major Companies of Genetically Modified Organisms/Crops
Table 20. Major Companies of Cell Line Engineering
Table 21. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 22. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019-2024) & (US$ Million)
Table 23. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2025-2030) & (US$ Million)
Table 24. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2019-2024)
Table 25. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2025-2030)
Table 26. Major Companies of Biotechnology Companies
Table 27. Major Companies of Pharmaceutical Companies
Table 28. Major Companies of Academic Institutes
Table 29. Major Companies of Research and Development Institutes
Table 30. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019-2024) & (US$ Million)
Table 32. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2025-2030) & (US$ Million)
Table 33. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2019-2024)
Table 34. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2025-2030)
Table 35. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2019-2024) & (US$ Million)
Table 37. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region (2019-2024)
Table 38. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2025-2030) & (US$ Million)
Table 39. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region (2025-2030)
Table 40. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2019-2024) & (US$ Million)
Table 42. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Market Share by Country (2019-2024)
Table 43. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2025-2030) & (US$ Million)
Table 44. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Market Share by Country (2025-2030)
Table 45. Thermo Fisher Scientific Company Information
Table 46. Thermo Fisher Scientific Business Overview
Table 47. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 48. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 49. Thermo Fisher Scientific Recent Development
Table 50. Editas Medicine Company Information
Table 51. Editas Medicine Business Overview
Table 52. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 53. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 54. Editas Medicine Recent Development
Table 55. Caribou Biosciences Company Information
Table 56. Caribou Biosciences Business Overview
Table 57. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 58. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 59. Caribou Biosciences Recent Development
Table 60. CRISPR therapeutics Company Information
Table 61. CRISPR therapeutics Business Overview
Table 62. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 63. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 64. CRISPR therapeutics Recent Development
Table 65. Intellia therapeutics, Inc. Company Information
Table 66. Intellia therapeutics, Inc. Business Overview
Table 67. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 68. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 69. Intellia therapeutics, Inc. Recent Development
Table 70. Cellectis Company Information
Table 71. Cellectis Business Overview
Table 72. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 73. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 74. Cellectis Recent Development
Table 75. Horizon Discovery Plc Company Information
Table 76. Horizon Discovery Plc Business Overview
Table 77. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 78. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 79. Horizon Discovery Plc Recent Development
Table 80. Sigma Aldrich Company Information
Table 81. Sigma Aldrich Business Overview
Table 82. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 83. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 84. Sigma Aldrich Recent Development
Table 85. Precision Biosciences Company Information
Table 86. Precision Biosciences Business Overview
Table 87. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 88. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 89. Precision Biosciences Recent Development
Table 90. Genscript Company Information
Table 91. Genscript Business Overview
Table 92. Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 93. Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 94. Genscript Recent Development
Table 95. Sangamo Biosciences Inc. Company Information
Table 96. Sangamo Biosciences Inc. Business Overview
Table 97. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 99. Sangamo Biosciences Inc. Recent Development
Table 100. Lonza Group Limited Company Information
Table 101. Lonza Group Limited Business Overview
Table 102. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 104. Lonza Group Limited Recent Development
Table 105. Integrated DNA Technologies Company Information
Table 106. Integrated DNA Technologies Business Overview
Table 107. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 109. Integrated DNA Technologies Recent Development
Table 110. New England Biolabs Company Information
Table 111. New England Biolabs Business Overview
Table 112. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 114. New England Biolabs Recent Development
Table 115. Origene Technologies Company Information
Table 116. Origene Technologies Business Overview
Table 117. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 119. Origene Technologies Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Authors List of This Report
Table 122. Secondary Sources
Table 123. Primary Sources
Table 1. CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
Table 2. CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
Table 3. CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
Table 4. CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints
Table 5. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Company (2019-2024)
Table 7. Global CRISPR and CRISPR-Associated (Cas) Genes Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global CRISPR and CRISPR-Associated (Cas) Genes Key Company Manufacturing Base & Headquarters
Table 9. Global CRISPR and CRISPR-Associated (Cas) Genes Company, Product Type & Application
Table 10. Global CRISPR and CRISPR-Associated (Cas) Genes Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global CRISPR and CRISPR-Associated (Cas) Genes by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Genome Editing
Table 15. Major Companies of Genetic engineering
Table 16. Major Companies of gRNA Database/Gene Librar
Table 17. Major Companies of CRISPR Plasmid
Table 18. Major Companies of Human Stem Cells
Table 19. Major Companies of Genetically Modified Organisms/Crops
Table 20. Major Companies of Cell Line Engineering
Table 21. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 22. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019-2024) & (US$ Million)
Table 23. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2025-2030) & (US$ Million)
Table 24. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2019-2024)
Table 25. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2025-2030)
Table 26. Major Companies of Biotechnology Companies
Table 27. Major Companies of Pharmaceutical Companies
Table 28. Major Companies of Academic Institutes
Table 29. Major Companies of Research and Development Institutes
Table 30. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019-2024) & (US$ Million)
Table 32. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2025-2030) & (US$ Million)
Table 33. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2019-2024)
Table 34. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2025-2030)
Table 35. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2019-2024) & (US$ Million)
Table 37. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region (2019-2024)
Table 38. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2025-2030) & (US$ Million)
Table 39. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region (2025-2030)
Table 40. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2019-2024) & (US$ Million)
Table 42. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Market Share by Country (2019-2024)
Table 43. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2025-2030) & (US$ Million)
Table 44. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Market Share by Country (2025-2030)
Table 45. Thermo Fisher Scientific Company Information
Table 46. Thermo Fisher Scientific Business Overview
Table 47. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 48. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 49. Thermo Fisher Scientific Recent Development
Table 50. Editas Medicine Company Information
Table 51. Editas Medicine Business Overview
Table 52. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 53. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 54. Editas Medicine Recent Development
Table 55. Caribou Biosciences Company Information
Table 56. Caribou Biosciences Business Overview
Table 57. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 58. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 59. Caribou Biosciences Recent Development
Table 60. CRISPR therapeutics Company Information
Table 61. CRISPR therapeutics Business Overview
Table 62. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 63. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 64. CRISPR therapeutics Recent Development
Table 65. Intellia therapeutics, Inc. Company Information
Table 66. Intellia therapeutics, Inc. Business Overview
Table 67. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 68. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 69. Intellia therapeutics, Inc. Recent Development
Table 70. Cellectis Company Information
Table 71. Cellectis Business Overview
Table 72. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 73. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 74. Cellectis Recent Development
Table 75. Horizon Discovery Plc Company Information
Table 76. Horizon Discovery Plc Business Overview
Table 77. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 78. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 79. Horizon Discovery Plc Recent Development
Table 80. Sigma Aldrich Company Information
Table 81. Sigma Aldrich Business Overview
Table 82. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 83. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 84. Sigma Aldrich Recent Development
Table 85. Precision Biosciences Company Information
Table 86. Precision Biosciences Business Overview
Table 87. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 88. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 89. Precision Biosciences Recent Development
Table 90. Genscript Company Information
Table 91. Genscript Business Overview
Table 92. Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2019-2024)
Table 93. Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 94. Genscript Recent Development
Table 95. Sangamo Biosciences Inc. Company Information
Table 96. Sangamo Biosciences Inc. Business Overview
Table 97. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 99. Sangamo Biosciences Inc. Recent Development
Table 100. Lonza Group Limited Company Information
Table 101. Lonza Group Limited Business Overview
Table 102. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 104. Lonza Group Limited Recent Development
Table 105. Integrated DNA Technologies Company Information
Table 106. Integrated DNA Technologies Business Overview
Table 107. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 109. Integrated DNA Technologies Recent Development
Table 110. New England Biolabs Company Information
Table 111. New England Biolabs Business Overview
Table 112. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 114. New England Biolabs Recent Development
Table 115. Origene Technologies Company Information
Table 116. Origene Technologies Business Overview
Table 117. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
Table 119. Origene Technologies Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Authors List of This Report
Table 122. Secondary Sources
Table 123. Primary Sources
LIST OF FIGURES
Figure 1. CRISPR and CRISPR-Associated (Cas) Genes Product Picture
Figure 2. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (2019-2030) & (US$ Million)
Figure 4. Global CRISPR and CRISPR-Associated (Cas) Genes Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Genome Editing Picture
Figure 8. Genetic engineering Picture
Figure 9. gRNA Database/Gene Librar Picture
Figure 10. CRISPR Plasmid Picture
Figure 11. Human Stem Cells Picture
Figure 12. Genetically Modified Organisms/Crops Picture
Figure 13. Cell Line Engineering Picture
Figure 14. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share 2019 VS 2023 VS 2030
Figure 16. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2019-2030)
Figure 17. Biotechnology Companies Picture
Figure 18. Pharmaceutical Companies Picture
Figure 19. Academic Institutes Picture
Figure 20. Research and Development Institutes Picture
Figure 21. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share 2019 VS 2023 VS 2030
Figure 23. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2019-2030)
Figure 24. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 25. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 26. North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)
Figure 27. North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030
Figure 28. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030
Figure 30. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030
Figure 32. Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)
Figure 33. Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030
Figure 36. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 37. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 38. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 39. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 40. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 41. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 42. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 43. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 44. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 45. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 46. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 47. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 48. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 49. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 50. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)
Figure
Figure 1. CRISPR and CRISPR-Associated (Cas) Genes Product Picture
Figure 2. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (2019-2030) & (US$ Million)
Figure 4. Global CRISPR and CRISPR-Associated (Cas) Genes Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Genome Editing Picture
Figure 8. Genetic engineering Picture
Figure 9. gRNA Database/Gene Librar Picture
Figure 10. CRISPR Plasmid Picture
Figure 11. Human Stem Cells Picture
Figure 12. Genetically Modified Organisms/Crops Picture
Figure 13. Cell Line Engineering Picture
Figure 14. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share 2019 VS 2023 VS 2030
Figure 16. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2019-2030)
Figure 17. Biotechnology Companies Picture
Figure 18. Pharmaceutical Companies Picture
Figure 19. Academic Institutes Picture
Figure 20. Research and Development Institutes Picture
Figure 21. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share 2019 VS 2023 VS 2030
Figure 23. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2019-2030)
Figure 24. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 25. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 26. North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)
Figure 27. North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030
Figure 28. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030
Figure 30. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030
Figure 32. Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)
Figure 33. Latin America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2023 VS 2030
Figure 36. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 37. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 38. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 39. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 40. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 41. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 42. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 43. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 44. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 45. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 46. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 47. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 48. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 49. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 50. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2023 VS 2030 & (%)
Figure
